Background of the study: Preterm infants are managed with antibiotics for sepsis, including suspected or probable sepsis. This leads to a delayed and abnormal colonization of the gut with potentially pathogenic organisms and a microbiome, which lacks biodiversity and increases the risk for late-onset sepsis (LOS). Probiotics have been proven to reduce the risk for necrotizing enterocolitis, but evidence for prevention of LOS is inconclusive. Probiotic effect depends also on the strain used, dose and indication for use. This study evaluated Bacillus clausii probiotic administered prophylactically to preterm neonates for prevention of LOS.
I N T R O D U C T I O N
Late-onset sepsis (LOS) occurs in preterm infants [1] with the reported incidence of 30 per 1000 live births [2, 3] . Recent studies from tertiary care institutes have reported emergence of drug-resistance organisms [4, 5] . Predisposing factors for sepsis include low birth weight, prematurity and admission to intensive care unit, among others [6, 7] . Susceptibility of preterm infants results from developmental immaturity of the immune system and abnormal proliferation of their gastrointestinal microflora. Normally this microbiome encompasses microorganisms acquired from the mother's vaginal canal, skin surface and milk and plays a role in immunoregulation and limiting colonization with pathogenic microbes [8] [9] [10] . Preterm infants acquire colonizing bacteria from the intensive care environment. Exposure to antibiotics after birth and prolonged hospitalization reduce the microbial diversity of this microbiome [11] [12] [13] . In this population at risk for LOS, colonization with commensals may improve following administration of oral probiotics [14] . Probiotics are live microorganisms, and oral administration protects the host from gastrointestinal and urinary infections by improving the integrity of the mucosal barrier, augmentation of immunoglobulin-A responses, production of bacteriocins and competitive exclusion of potential pathogens [15] . Evidence-based guidelines, systematic reviews and meta-analyses on probiotic use in preterm infants have been published [16] [17] [18] . The Cochrane systematic review in preterm infants found no evidence of significant reduction of nosocomial sepsis probably owing to heterogeneity of the included studies, although earlier randomized controlled trials (RCT) showed a significant difference [19, 20] . A recently published RCT using a probiotic combination of Bifidobacterium infantis, Streptococcus thermophiles and Bifidobacterium lactis showed a significant reduction in LOS in preterm subgroup of 28-31 weeks gestation [21] .
There is limited published data on role of probiotics for prevention of LOS, and antimicrobial use for prevention of LOS is associated with drug resistance and other side effects. Therefore, we conducted this trial to evaluate prophylactic oral Bacillus clausii in preterm infants for prevention of definite or probable LOS during the postnatal period.
M E T H O D S
The study was a double-blinded, placebo-controlled, randomized trial, conducted from 1 March 2012 to 28 February 2014 at a tertiary care unit in India providing preterm neonatal intensive care with ventilation, indwelling lines, parenteral nutrition and intravenous (IV) antibiotic for early-onset sepsis (EOS). In asymptomatic preterm infants with suspected sepsis, antibiotics were stopped with a sterile blood culture and negative C-reactive protein (CRP) by day 3-5. Antibiotics were stopped by day 7-10 in symptomatic preterm infants after the baby had been weaned off respiratory and/or inotropic support, was on minimal enteral nutrition or enteral feeding, with daily feed advancement and a negative blood culture and CRP. Antibiotic used was as per the neonatal intensive care unit (NICU) antibiotic policy. Methods for prevention of sepsis in the NICU were in place. Gestational age was assessed from early scans or by Ballard scoring. The study was approved by the institutional ethics committee.
Enrolment criteria
Preterm neonates <34 weeks admitted to the NICU were prospectively enrolled after obtaining written informed consent from the parents.
Exclusion criteria i. Extramural preterm neonates >10 day age with clinical or lab marker of sepsis. ii. Preterm babies with necrotizing enterocolitis (NEC) or an intestinal surgical anomaly. iii. Preterm babies with a lethal congenital anomaly, dysmorphism or aneuploidy.
Randomization. Serially admitted preterm neonates <34 weeks eligible for the study were enrolled and stratified as Extreme preterm (27-30 weeks 6 days) or Very preterm (31-33 weeks 6 days). On stopping of IV antibiotic, the enrolled neonate was randomized to receive either probiotic or placebo. Randomization was done using an online service (www.randomization.com).
Intervention. Intervention was started typically by day 5 in asymptomatic and day 10 in symptomatic neonates. Babies in the probiotic group received probiotic suspension of Bacillus clausii containing 2 Â 10 9 spores in 5 ml minibottle (Enterogermina, SanofiAventis, Italy) in a dose of 2 ml per-oral every 8 hours mixed with the enteral feeds through orogastric tube or oral feeds, giving them 2.4 Â 10 9 spores per day. Probiotic supplementation was continued till postnatal age of 6 weeks, or till discharge or death or occurrence of LOS, whichever was earlier for babies in both the very preterm and the extreme preterm group. Babies in the placebo group received sterile water, 2 ml per-oral every 8 hours mixed with feeds. Both the probiotic and the placebo were dispensed in 2 ml syringes and were identical in appearance. All babies received minimal enteral nutrition beginning after 24 h of age. Intrauterine growth-restricted babies with abnormal umbilical artery doppler were kept nil orally for 48 h. Babies in both the groups were fed expressed breast milk (EBM). In the absence of EBM, donor breast milk was used. Feed advancement was done following a standardized feeding regime.
Monitoring. Monitoring of heart rate, respiratory distress score, temperature, pulse oximetry, capillary refill time, non-invasive blood pressure, blood sugar by glucometer, abdominal distention, prefeed residue volume and colour and stool volume and colour was done. Investigations sent on admission to NICU were complete blood counts, blood culture and venous blood gas. CRP, peripheral blood smear (PBS), serum sodium and potassium were done on day 3. Between day 5 and 7, CRP, blood culture and stool culture were sent; CRP, PBS and blood culture were sent in case of suspicion of sepsis between days 7 and 28. The intervention was stopped and baby was investigated for sepsis with one or more of the following:
i. Prefeed gastric aspirate or vomit that is bilious or contains blood. ii. New onset apnoea or an increase in FiO2 by >10%. iii. Blood sugar disturbances-hypo-or hyperglycemia. iv. Capillary refill time (CRT) > 5 s or hypotension needing inotopic support. v. Clinical coagulopathy.
Blood culture was drawn and empirical antibiotic therapy instituted. Supportive measures as necessary were given. In addition evaluation with a CRP and PBS was done. A CRP >10 mg/l and PBS showing left shift with leukocytosis, leucopenia, thrombocytopenia was considered as probable sepsis. Neonate with a pure growth on blood culture was labelled as having definite sepsis.
Primary outcome. Incidence of definite and probable LOS in preterm neonates <34 weeks prophylactically administered oral probiotic compared with placebo.
Secondary outcome. Secondary outcomes were time to attainment of full feeds taken as 180 ml/kg, overall duration of antibiotic use, NEC, duration of hospital stay and all-cause mortality.
Blinding. All the investigators were blinded to the intervention. Serially numbered opaque sealed envelopes with the allocation were available with the in-charge nurse of the NICU, who dispensed the intervention in a syringe for oral administration. All probiotic and sterile water minibottles were coded and labels concealed. Unused portions of either the probiotic or the placebo were discarded. Sample size calculation. The incidence of LOS in preterm neonates in our NICU during the period 2010-11 was 21%, similar to other institutions. Assuming a 15% reduction in the incidence with use of probiotics, with an a-error of 5%, b-error of 20% and power of the study at 80%, the sample size required was 125 cases in each arm.
Statistical analysis. Descriptive statistics were used to describe the baseline variables. Categorical outcome variables were compared by Chi-square test or Fisher's exact test wherever one or more expected cell size was <5. p value of 0.05 was taken as significant. Statistical analysis was done using software package SPSS version 17.0 and Microsoft Excel. Intention to treat analysis was done.
R E S U L T S
A total of 326 babies were eligible for inclusion. Eightytwo babies were excluded (did not give consent-16, died-09, perinatal asphyxia-08, life threatening malformation-13, surgical abdomen-04, sepsis needing antibiotics beyond 10th day-15, dysmorphism or aneuploidy-10, overlooked for enrolment-07) (Fig. 1) . In the excluded cases, four deaths were owing to EOS with shock, three from hypoxemic respiratory failure and one each from pneumothorax and massive pulmonary haemorrhage. Babies in both the groups had comparable baseline characteristics ( Table  1) . Implementation of the intervention was similar in both the groups (Table 2) . Indications for prematurity were similarly distributed (Fig. 2) . The number of blood culture positive cases in the extreme preterm group was 14, while in the very preterm group was 5. Two cases were diagnosed as meningitis based on cerebrospinal fluid (CSF) criteria. Bacteria isolated on the blood cultures were Klebseilla pneumonia-four, Acinetobacter baumanii-four, Pseudomonas aeruginosa-two, Enterococcus faecium-two and coagulase negative Staphylococcus-seven. There was no significant difference between the incidence of definite and probable sepsis between the two arms in the extreme preterm group [29% vs. 23%; relative risk (RR) 1.27; 95% confidence interval (CI) 0.88-1.66; p ¼ 0.36] and the very preterm group (13% vs. 10%; RR 1.33; 95% CI 0.96-1.70; p ¼ 0.32) ( Table 3 ). There was faster attainment of full feeds (180 ml/kg/day) in babies randomized to the probiotic group in both the extreme preterm (RR 0.82; 95% CI 0.74-0.88) and the very preterm (RR 0.67; 95% 0.32-0.77) ( Table 4) . D I S C U S S I O N Evaluation of prophylactic probiotics for preventing LOS has not yielded firm recommendations owing to heterogeneity in the conduct of RCT with respect to the probiotic strains studied, the method of administration and small numbers of extremely low birth weight (ELBW) as a subgroup. It is increasingly recognized that prolonged antibiotic exposure in neonates with suspected sepsis and a negative blood culture increases the risk of LOS, NEC and death [22, 23] . Probiotic effects are dose, condition and strain specific [24] . RCT on preterm supplementation with Bifidobacterium lactis or Lactobacillus containing probiotic have not resulted in a consistent reduction in the risk of LOS, and there are reports of blood culture positive sepsis with the probiotic bacteria [25, 26] . In ELBW neonates, a single bacterium probiotic is preferable [16] . Bacillus clausii has previously not been evaluated for this purpose in preterm neonates. The selection of this probiotic was guided by its safety and approval for use in breastfed neonates, liquid formulation obviating issues of reconstitution, accuracy of dosing, direct antimicrobial properties and stimulation of lymphocytic activity in Peyer's patches increasing IgA-positive lymphocytes resulting in reduced bacterial gut translocation [27] [28] [29] . Additionally, mothers own or donor EBM for feeding provided babies with the benefit of Bifidobacterium and Lactobacillus. This study did not show a significant difference in the incidence of blood culture proven or probable sepsis in the placebo arm compared with the probiotic arm of the extreme preterm (29% vs. 23%) and the very preterm (13% vs. 10%) groups. Inability to show a significant difference in the incidence of LOS may have been owing to rigorous implementation of a sepsis control bundle and use of EBM in the NICU. A greater proportion of babies in the placebo arm of both the study groups had intervention discontinued. This difference was 10% in the extreme preterm group, but was not significant. Intervention discontinuation owing to feed intolerance was similar between the study groups. There was a significantly faster attainment of feed volumes of 180 ml/kg/day by the babies in the probiotic arm in both the study groups, which has not been observed in earlier studies [21, 25, 30] . There were no differences in the incidence of NEC, duration of antibiotics and duration of hospitalization and all-cause mortality between the placebo and probiotic arms of both the study groups. There were similar numbers of sepsis-related deaths in both groups. Earlier trials have differed with respect to the probiotic, use of multi-strain preparation, comparison of live vs. killed bacteria and different dosing and duration strategy [21, [30] [31] [32] . The strength of this study was its doubleblinded design and enrolment of ELBW babies. Our study demonstrated the safety and tolerance of B.clausii in preterms and a clinically significant faster attainment of full feed volume without an increased risk of feed intolerance or NEC. There is a need for studies comparing B.clausii with other combination probiotics, with larger sample size of ELBW babies.
